A Phase I/II Study to Evaluate the Safety and Efficacy of Vinorelbine With Trastuzumab Emtansine in Pre-Treated HER2-Positive Metastatic Breast Cancer

Trial Profile

A Phase I/II Study to Evaluate the Safety and Efficacy of Vinorelbine With Trastuzumab Emtansine in Pre-Treated HER2-Positive Metastatic Breast Cancer

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 16 Apr 2018

At a glance

  • Drugs Trastuzumab emtansine (Primary) ; Vinorelbine (Primary)
  • Indications Breast cancer; Male breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 11 Apr 2018 Status changed from recruiting to active, no longer recruiting.
    • 10 Jun 2017 Biomarkers information updated
    • 10 Apr 2017 Planned primary completion date changed from 1 Oct 2021 to 1 Jul 2022.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top